These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 14573975

  • 1. Visual outcome in macular retinoblastoma treated with primary chemotherapy.
    Balasubramanya R, Pushker N, Bajaj MS, Rani A, Ghose S, Arya LS.
    Ophthalmologica; 2003; 217(6):417-21. PubMed ID: 14573975
    [Abstract] [Full Text] [Related]

  • 2. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, Shields JA.
    Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
    [Abstract] [Full Text] [Related]

  • 3. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
    Künkele A, Jurklies C, Wieland R, Lohmann D, Bornfeld N, Eggert A, Schulte JH.
    Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
    [Abstract] [Full Text] [Related]

  • 4. Long-term visual outcome following chemoreduction for retinoblastoma.
    Demirci H, Shields CL, Meadows AT, Shields JA.
    Arch Ophthalmol; 2005 Nov; 123(11):1525-30. PubMed ID: 16286614
    [Abstract] [Full Text] [Related]

  • 5. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
    Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG.
    Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
    [Abstract] [Full Text] [Related]

  • 6. Chemoreduction for unilateral retinoblastoma.
    Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ.
    Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
    [Abstract] [Full Text] [Related]

  • 7. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
    Shields CL, Shields JA, Needle M, de Potter P, Kheterpal S, Hamada A, Meadows AT.
    Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective phase II study of children affected by bilateral intraocular retinoblastoma with macular involvement of both eyes or in the only preserved eye. Macular tumor control, eye preservation rate, and visual outcome.
    Russo I, Levy-Gabriel C, Dupont A, Lumbroso-Le Rouic L, Cassoux N, Desjardins L, Bertozzi AI, Coze C, Doz F, Savignoni A, Aerts I.
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28721. PubMed ID: 33098751
    [Abstract] [Full Text] [Related]

  • 10. Management and outcome of retinoblastoma with vitreous seeds.
    Manjandavida FP, Honavar SG, Reddy VA, Khanna R.
    Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
    [Abstract] [Full Text] [Related]

  • 11. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.
    Bartuma K, Pal N, Kosek S, Holm S, All-Ericsson C.
    Acta Ophthalmol; 2014 Aug; 92(5):404-11. PubMed ID: 24119165
    [Abstract] [Full Text] [Related]

  • 12. Restoration of foveal anatomy and function following chemoreduction for bilateral advanced retinoblastoma with total retinal detachment.
    Shields CL, Materin MA, Shields JA.
    Arch Ophthalmol; 2005 Nov; 123(11):1610-2. PubMed ID: 16286630
    [No Abstract] [Full Text] [Related]

  • 13. Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments.
    Kim JM, Kim JH, Kim SJ, Park KD, Shin HY, Ahn HS, Yu YS.
    Korean J Ophthalmol; 2010 Dec; 24(6):347-52. PubMed ID: 21165233
    [Abstract] [Full Text] [Related]

  • 14. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
    Shields CL, Shelil A, Cater J, Meadows AT, Shields JA.
    Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
    [Abstract] [Full Text] [Related]

  • 15. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
    Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO.
    Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA.
    Trans Am Ophthalmol Soc; 2004 Oct; 102():35-44; discussion 44-5. PubMed ID: 15747743
    [Abstract] [Full Text] [Related]

  • 18. Clinical result of prolonged primary chemotherapy in retinoblastoma patients.
    Kim JH, Yu YS, Khwarg SI, Choi HS, Shin HY, Ahn HS.
    Korean J Ophthalmol; 2003 Jun; 17(1):35-43. PubMed ID: 12882506
    [Abstract] [Full Text] [Related]

  • 19. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
    Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, Shields JA.
    Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
    [Abstract] [Full Text] [Related]

  • 20. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
    Demirci H, Eagle RC, Shields CL, Shields JA.
    Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.